Alnylam Pharmaceuticals is partnering with Inceptive Nucleics in a deal that aligns with the growing biopharmaceutical trend of using generative AI to support drug development.
A Massachusetts biotech company is offering $30 million for access to Inceptive’s machine learning engine to accelerate the discovery and development of new drug candidates, according to one source. Wednesday press release. Overall, the value of the backloaded deal could reach up to $2 billion, including preclinical, regulatory, and commercial milestones.
Inceptive’s AI models can identify and learn the underlying biological processes surrounding specific diseases and adapt to different treatments without retraining, the companies said.
By leveraging such a platform, Alnylam hopes to optimize the design and selection of siRNA by considering the molecule’s sequence and chemical modifications, “prioritizing the most promising molecules and increasing experimental productivity,” the biotech company announced Wednesday.
Biopharma has been rapidly integrating advanced AI models into its drug development business in recent weeks.
Last month, Eli Lilly, Bristol-Myers Squibb, and Insight each brought Each AI partner works together to improve efficiency in different areas of your business.
A few days ago, Isomorphic Labs $2.1 billion Analysts at the time said the funding round was the second largest biotech financing in history. Isomorphic was able to raise this amount even though the clinic had no assets.
AI also helps biotech public markets, experts say biospace It was announced earlier this year that the technology is helping drive an increase in initial public offerings in 2026.
“AI is fundamentally changing the risk calculus in biotech investing,” Tyrone Lamb, chief business officer of AI-focused tech-bio company GATC Health, said in an April interview.
For Alnylam, the inceptive agreement follows a collaboration in March with Tenaya Therapeutics focused on developing RNA interference therapies for cardiovascular disease. That partnership cost Alnylam $10 million upfront Another $1.13 billion milestone is possible.
The recent increase in IPOs is an encouraging sign after a drought for much of 2025. Experts point to AI as a driving force behind this resurgence.
